Epstein Secrets

omething on the table." Reuters (10/22, Cornwell) reports, "Senate Republicans remained skeptical of a possible deal costing trillions of dollars." Senate Appropriations Chairman Shelby told reporters, "I think we're not going anywhere. A lot of talk, no action." The Washington Post (10/22, Werner, Stein, 14.2M) say

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

-republicans-wary-idUSKBN2771VQ> (10/22, Cornwell) reports, "Senate Republicans remained skeptical of a possible deal costing trillions of dollars." Senate Appropriations Chairman Shelby told reporters, "I think we're not going anywhere. A lot of talk, no action." The Washington Post <https://vvww.washingtonpost.com/

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

omething on the table." Reuters (10/22, Cornwell) reports, "Senate Republicans remained skeptical of a possible deal costing trillions of dollars." Senate Appropriations Chairman Shelby told reporters, "I think we're not going anywhere. A lot of talk, no action." The Washington Post (10/22, Werner, Stein, 14.2M) say

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug